Glutathione Depletion and MicroRNA Dysregulation in Multiple System Atrophy: A Review

Chisato Kinoshita1, Noriko Kubota1,2, Koji Aoyama1

  • 1Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan.

Insights

Multiple system atrophy (MSA) involves oxidative stress, potentially linked to glutathione deficiency and microRNA (miRNA) dysregulation. This review explores their connection to MSA pathology, offering insights into this rare neurodegenerative disease.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Multiple system atrophy (MSA) is a rare neurodegenerative disorder with uncertain etiology.
  • Oxidative stress, involving reactive oxygen species and antioxidant system imbalance, is implicated in MSA pathogenesis.
  • Glutathione, a critical antioxidant in the central nervous system, is depleted in neurodegenerative conditions.
  • MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression and are implicated in disease.

Purpose of the Study:

  • To review the relationship between glutathione deficiency, miRNA dysregulation, and oxidative stress in the context of MSA pathology.
  • To elucidate the potential roles of these factors in the onset and progression of MSA.

Main Methods:

  • Literature review focusing on studies investigating glutathione, miRNAs, oxidative stress, and MSA.
  • Synthesis of findings from existing research to establish connections between these elements.

Main Results:

  • Glutathione levels are reduced in neurodegenerative diseases, including MSA.
  • miRNAs are dysregulated in MSA and can post-transcriptionally modify genes involved in redox regulation.
  • A strong link exists between glutathione deficiency, miRNA dysregulation, and oxidative stress in MSA pathology.

Conclusions:

  • Glutathione deficiency and miRNA dysregulation are closely associated with oxidative stress and contribute to the pathology of Multiple System Atrophy.
  • Understanding these interactions may provide novel therapeutic targets for MSA.